Clinical Trial Update: CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide

View source ↗

Summary

A clinical trial update investigates whether CYP3A5 gene variants influence the risk of kidney damage in young cancer patients treated with ifosfamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Unspecified Childhood Solid Tumor

Drugs mentioned

• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Children's Cancer and Leukaemia Group | Conditions: Chemotherapeutic Agent Toxicity, Sarcoma | Status: UNKNOWN